Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Risk factors for calcium stones in adults

INTRODUCTION

Renal stone disease (nephrolithiasis) is a relatively common problem [1,2]. Older studies estimated that 12 percent of men and 5 percent of women will have at least one symptomatic stone by the age of 70 [1].

In a report from the third National Health and Nutrition Examination Survey, the population prevalence increased from 3.8 percent in the period 1976 to 1980 to 5.2 percent in the years 1988 to 1994 [2]. The prevalence increased in men and women, and whites and blacks. However, the incidence rates since then may have leveled off [3].

Approximately 75 percent of patients with nephrolithiasis form calcium stones, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate [1,4]. Pure uric acid stones make up less than 10 percent of all stones.

This topic provides an overview of the pathogenesis and risk factors for calcium nephrolithiasis. The evaluation and management of the patient with kidney stones, prevention of recurrent calcium stones, and related topics are discussed separately. (See "Diagnosis and acute management of suspected nephrolithiasis in adults" and "Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown" and "Prevention of recurrent calcium stones in adults".)

PATHOGENESIS

Stones are more likely to occur when one or more factors are present that lead sequentially to supersaturation of the urine, the formation of crystals, and their subsequent aggregation into a clinically detectable stone. Even individuals without nephrolithiasis can excrete crystals; however, calcium oxalate stone formers are more likely to have crystalluria than controls, and the presence of crystalluria substantially increases the likelihood of stone formation (picture 1A-B) [5].

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2010 UpToDate, Inc.
References Top
  1. Johnson, CM, Wilson, DM, O'Fallon, WM, et al. Renal stone epidemiology: A 25-year study in Rochester, Minnesota. Kidney Int 1979; 16:624.
  2. Stamatelou, KK, Francis, ME, Jones, CA, Nyberg, LM. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003; 63:1817.
  3. Lieske, JC, Pena de, la Vega LS, Slezak, JM, et al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int 2006; 69:760.
  4. Coe, FL, Parks, JH, Asplin, JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.
  5. Robertson, WG, Peacock, M. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 1972; 43:499.
  6. Kumar, V, Pena de, la Vega L, Farell, G, Lieske, JC. Urinary macromolecular inhibition of crystal adhesion to renal epithelial cells is impaired in male stone formers. Kidney Int 2005; 68:1784.
  7. Sheng, X, Ward, MD, Wesson, JA. Crystal surface adhesion explains the pathological activity of calcium oxalate hydrates in kidney stone formation. J Am Soc Nephrol 2005; 16:1904.
  8. Kok, DJ, Khan, SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 1994; 46:847.
  9. Asselman, M, Verhulst, A, De Broe, ME, Verkoelen, CF. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003; 14:3155.
  10. Evan, AP, Lingeman, JE, Coe, FL, et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111:607.
  11. Evan, AP, Coe, FL, Rittling, SR, et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 2005; 68:145.
  12. Evan, A, Lingeman, J, Coe, FL, Worcester, E. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 2006; 69:1313.
  13. Matlaga, BR, Williams, JC Jr, Kim, SC, et al. Endoscopic evidence of calculus attachment to Randall's plaque. J Urol 2006; 175:1720.
  14. Parks, JH, Coe, FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 1986; 30:85.
  15. Bihl, G, Meyers, A. Recurrent renal stone disease-advances in pathogenesis and clinical management. Lancet 2001; 358:651.
  16. Atan, L, Andreoni, C, Ortiz, V, et al. High kidney stone risk in men working in steel industry at hot temperatures. Urology 2005; 65:858.
  17. Coe, FL, Evan, A, Worcester, E. Kidney stone disease. J Clin Invest 2005; 115:2598.
  18. Borghi, L, Schianchi, T, Meschi, T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77.
  19. Curhan, GC, Willett, WC, Rimm, EB, Stampfer, MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328:833.
  20. Gault, MH, Chafe, LL, Morgan, JM, et al. Comparison of patients with idiopathic calcium phosphate and calcium oxalate stones. Medicine (Baltimore) 1991; 70:345.
  21. Curhan, GC, Taylor, EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int 2008; 73:489.
  22. Trinchieri, A, Rovera, F, Nespoli, R, Curro, A. Clinical observations on 2086 patients with upper urinary tract stone. Arch Ital Urol Androl 1996; 68:251.
  23. Corbetta, S, Baccarelli, A, Aroldi, A, et al. Risk factors associated to kidney stones in primary hyperparathyroidism. J Endocrinol Invest 2005; 28:122.
  24. Pak, CY. Etiology and treatment of urolithiasis. Am J Kidney Dis 1991; 18:624.
  25. Frick, KK, Bushinsky, DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Nephrol 2003; 14:1082.
  26. Reed, BY, Heller, HJ, Gitomer, WL, Pak, CY. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3- q24. J Clin Endocrinol Metab 1999; 84:3907.
  27. Wolf, MT, Zalewski, I, Martin, FC, et al. Mapping a new suggestive gene locus for autosomal dominant nephrolithiasis to chromosome 9q33.2-q34.2 by total genome search for linkage. Nephrol Dial Transplant 2005; 20:909.
  28. Gambaro, G, Vezzoli, G, Casari, G, et al. Genetics of hypercalciuria and calcium nephrolithiasis: From the rare monogenic to the common polygenic forms. Am J Kidney Dis 2004; 44:963.
  29. Moe, OW, Bonny, O. Genetic hypercalciuria. J Am Soc Nephrol 2005; 16:729.
  30. Bataille, P, Achard, JM, Fournier, A, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991; 39:1193.
  31. Lemann, J Jr, Worcester, EM, Gray, FW. Hypercalciuria and stones. Am J Kidney Dis 1991; 17:386.
  32. Adams, ND, Gray, RW, Lemann, J, Jr, Cheung, HS. Effects of calcitriol administration on calcium metabolism in healthy men. Kidney Int 1982; 21:90.
  33. Pietschmann, F, Breslau, NA, Pak, CY. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res 1992; 7:1383.
  34. Martini, LA, Cuppari, L, Colugnati, FA, et al. High sodium chloride intake is associated with low bone density in calcium stone-forming patients. Clin Nephrol 2000; 54:85.
  35. Misael da, Silva AM, dos Reis, LM, Pereira, RC, et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol 2002; 57:183.
  36. Asplin, JR, Bauer, KA, Kinder, J, et al. Bone mineral density and urine calcium excretion among subjects with and without nephrolithiasis. Kidney Int 2003; 63:662.
  37. Lau, YK, Wasserstein, A, Westby, GR, et al. Proximal tubular defects in idiopathic hypercalciuria: Resistance to phosphate administration. Miner Electrolyte Metab 1982; 7:237.
  38. Levi, M, Bruesegem, S. Renal phosphate-transporter regulatory proteins and nephrolithiasis. N Engl J Med 2008; 359:1171.
  39. Karim, Z, Gerard, B, Bakouh, N, et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N Engl J Med 2008; 359:1128.
  40. Prie, D, Beck, L, Silve, C, Friedlander, G. Hypophosphatemia and calcium nephrolithiasis. Nephron Exp Nephrol 2004; 98:e50.
  41. Rendina, D, Mossetti, G, De Filippo, G, et al. Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab 2006; 91:959.
  42. Alpern, RJ, Sakhaee, K. Does hyperphosphaturia underlie hypercalciuria? Lancet 1997; 349:518.
  43. Yao, J, Kathpalia, P, Bushinsky, DA, Favus, MJ. Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. J Clin Invest 1998; 101:2223.
  44. Scott, P, Ouimet, D, Valiquette, L, et al. Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 1999; 10:1007.
  45. Gambaro, G, Petrarulo, M, Nardelotto, A, et al. Erythrocyte transmembrane flux and renal clearance of oxalate in idiopathic calcium nephrolithiasis. Kidney Int 1995; 48:1549.
  46. Holmes, RP, Goodman, HO, Assimos, DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59:270.
  47. Smith, LH. Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis. Am J Kidney Dis 1991; 17:370.
  48. Taylor, EN, Curhan, GC. Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol 2007; 18:2198.
  49. Voss, S, Hesse, A, Zimmermann, DJ, et al. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [(13)C2]oxalate absorption test. J Urol 2006; 175:1711.
  50. Parks, JH, Worcester, EM, O'Connor, RC, Coe, FL. Urine stone risk factors in nephrolithiasis patients with and without bowel disease. Kidney Int 2003; 63:255.
  51. Annuk, M, Backman, U, Holmgren, K, Vessby, B. Urinary calculi and jejunoileal bypass operation. A long-term follow-up. Scand J Urol Nephrol 1998; 32:177.
  52. Hassan, I, Juncos, LA, Milliner, DS, et al. Chronic renal failure secondary to oxalate nephropathy: a preventable complication after jejunoileal bypass. Mayo Clin Proc 2001; 76:758.
  53. Dhar, NB, Grundfest, S, Jones, JS, Streem, SB. Jejunoileal bypass reversal: effect on renal function, metabolic parameters and stone formation. J Urol 2005; 174:1844.
  54. McConnell, N, Campbell, S, Gillanders, I, et al. Risk factors for developing renal stones in inflammatory bowel disease. BJU Int 2002; 89:835.
  55. Terribile, M, Capuano, M, Cangiano, G, et al. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol Dial Transplant 2006; 21:1870.
  56. Asplin, JR, Coe, FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 2007; 177:565.
  57. Sinha, MK, Collazo-Clavell, ML, Rule, A, et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007; 72:100.
  58. Williams, HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13:410.
  59. Kathpalia, SC, Favus, MJ, Coe, FL. Evidence for size and charge permselectivity of rat ascending colon. Effects of ricinoleate and bile salts on oxalic acid and neutral sugar transport. J Clin Invest 1984; 74:805.
  60. Obialo, CI, Clayman, RV, Matts, JP, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: Case-control study. The POSCH group. Kidney Int 1991; 39:1249.
  61. Hoppe, B, von Unruh, GE, Blank, G, et al. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis 2005; 46:440.
  62. Wharton, R, D'Agati, V, Magun, AM, et al. Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 1990; 34:116.
  63. Patel, BN, Passman, CM, Fernandez, A, et al. Prevalence of hyperoxaluria after bariatric surgery. J Urol 2009; 181:161.
  64. Sidhu, H, Hoppe, B, Hesse, A, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: A risk factor for hyperoxaluria. Lancet 1998; 352:1026.
  65. Mittal, RD, Kumar, R, Mittal, B, et al. Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium Oxalobacter formigenes as risk factors for renal stone formation. Med Princ Pract 2003; 12:208.
  66. Duncan, SH, Richardson, AJ, Kaul, P, et al. Oxalobacter formigenes and its potential role in human health. Appl Environ Microbiol 2002; 68:3841.
  67. Goldfarb, DS. Microorganisms and calcium oxalate stone disease. Nephron Physiol 2004; 98:p48.
  68. Hatch, M, Cornelius, J, Allison, M, et al. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006; 69:691.
  69. Kaufman, DW, Kelly, JP, Curhan, GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008; 19:1197.
  70. Lieske, JC, Goldfarb, DS, De Simone, C, Regnier, C. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int 2005; 68:1244.
  71. Jiang, Z, Asplin, JR, Evan, AP, et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006; 38:474.
  72. Urivetzky, M, Kessaris, D, Smith, AD. Ascorbic acid overdosing: A risk factor for calcium oxalate nephrolithiasis. J Urol 1992; 147:1215.
  73. Baxmann, AC, De O, G Mendonca C, Heilberg, IP. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int 2003; 63:1066.
  74. Traxer, O, Huet, B, Poindexter, J, Pak, CY. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003; 170:397.
  75. Massey, LK, Liebman, M, Kynast-Gales, SA. Ascorbate increases human oxaluria and kidney stone risk. J Nutr 2005; 135:1673.
  76. Taylor, EN, Stampfer, MJ, Curhan, GC. Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15:3225.
  77. Chai, W, Liebman, M, Kynast-Gales, S, Massey, L. Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis 2004; 44:1060.
  78. Rudman, D, Kutner, MH, Redd, SC II, et al. Hypocitricuria in calcium nephrolithiasis. J Clin Endocrinol Metab 1982; 55:1052.
  79. Asplin, JR, Parks, JH, Chen, MS, et al. Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 1999; 56:1505.
  80. Asplin, JR, Parks, JH, Nakagawa, Y, Coe, FL. Reduced crystallization inhibition by urine from women with nephrolithiasis. Kidney Int 2002; 61:1821.
  81. Wesson, JA, Johnson, RJ, Mazzali, M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003; 14:139.
  82. Kok, DJ, Papapoulos, SE, Bijvoet, OL. Crystal agglomeration is a major element in calcium oxalate urinary stone formation. Kidney Int 1990; 37:51.
  83. Okamoto, N, Aruga, S, Matsuzaki, S, et al. Associations between renal sodium-citrate cotransporter (hNaDC-1) gene polymorphism and urinary citrate excretion in recurrent renal calcium stone formers and normal controls. Int J Urol 2007; 14:344.
  84. Domrongkitchaiporn, S, Stitchantrakul, W, Kochakarn, W. Causes of hypocitraturia in recurrent calcium stone formers: focusing on urinary potassium excretion. Am J Kidney Dis 2006; 48:546.
  85. Donnelly, S, Kamel, KS, Vasuvattakul, S, et al. Might distal renal tubular acidosis be a proximal tubular cell disorder. Am J Kidney Dis 1992; 19:272.
  86. Lieske, JC, Toback, FG. Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 1993; 264:F800.
  87. Hess, B, Zipperle, L, Jaeger, P. Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 1993; 265:F784.
  88. Asplin, JR, Arsenault, D, Parks, JH, et al. Contribution of human uropontin to inhibition of calcium oxalate crystallization. Kidney Int 1998; 53:194.
  89. Min, W, Shiraga, H, Chalko, C, et al. Quantitative studies of human excretion of uropontin. Kidney Int 1998; 53:189.
  90. Mo, L, Huang, HY, Zhu, XH, et al. Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 2004; 66:1159.
  91. Ettinger, B, Tang, A, Citron, JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986; 315:1386.
  92. Yagisawa, T, Kobayashi, C, Hayashi, T, et al. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis 2001; 37:1140.
  93. Parks, JH, Coe, FL, Strauss, AL. Calcium nephrolithiasis and medullary sponge kidney in women. N Engl J Med 1982; 306:1088.
  94. Curhan, GC, Willett, WC, Rimm, EB, Stampfer, MJ. Family history and risk of kidney stones. J Am Soc Nephrol 1997; 8:1568.
  95. Serio, A, Fraioli, A. Epidemiology of nephrolithiasis. Nephron 1999; 81 Suppl 1:26.
  96. Curhan, GC, Willett, WC, Speizer, FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997; 126:497.
  97. Goodman, HO, Holmes, RP, Assimos, DG. Genetic factors in calcium oxalate stone disease. J Urol 1995; 153:301.
  98. Reddy, ST, Wang, CY, Sakhaee, K, et al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. Am J Kidney Dis 2002; 40:265.
  99. Goldfarb, DS, Fischer, ME, Keich, Y, Goldberg, J. A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. Kidney Int 2005; 67:1053.
  100. Kramer, HJ, Choi, HK, Atkinson, K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' follow-up study. Kidney Int 2003; 64:1022.
  101. Kramer, HM, Curhan, G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 2002; 40:37.
  102. Curhan, GC, Willett, WC, Rimm, EB, et al. Body size and risk of kidney stones. J Am Soc Nephrol 1998; 9:1645.
  103. Taylor, EN, Stampfer, MJ, Curhan, GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293:455.
  104. Taylor, EN, Stampfer, MJ; Curhan, GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005; 68:1230.
  105. Daudon, M, Lacour, B, Jungers, P. Influence of body size on urinary stone composition in men and women. Urol Res 2006; 34:193.
  106. Sarica, K, Altay, B, Erturhan, S. Effect of being overweight on stone-forming risk factors. Urology 2008; 71:771.
  107. Cameron, MA, Maalouf, NM, Adams-Huet, B, et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17:1422.
  108. Lee, CT, Lien, YH, Lai, LW, et al. Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. Kidney Int 2006; 69:1786.
  109. Maalouf, NM, Sakhaee, K, Parks, JH, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004; 65:1422.
  110. Taylor, EN, Curhan, GC. Body size and 24-hour urine composition. Am J Kidney Dis 2006; 48:905.
  111. Allen, SE, Singh, S, Robertson, WG. The increased risk of urinary stone disease in betel quid chewers. Urol Res 2006; 34:239.
  112. Parivar, F, Low, RK, Stoller, ML. Influence of diet on urinary stone disease. J Urol 1996; 155:432.
  113. Taylor, EN, Fung, TT, Curhan, GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009; 20:2253.
  114. Borghi, L, Meschi, T, Amato, F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. J Urol 1996; 155:839.
  115. Curhan, GC, Willett, WC, Knight, EL, Stampfer, MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. Arch Intern Med 2004; 164:885.
  116. Curhan, GC, Willett, WC, Speizer, FE, Stampfer, MJ. Beverage use and risk for kidney stones in women. Ann Intern Med 1998; 128:534.
  117. Curhan, G, Willett, WC, Rimm, EB, et al. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol 1996; 143:240.
  118. Honow, R, Laube, N, Schneider, A, et al. Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization. Br J Nutr 2003; 90:295.
  119. Trinchieri, A, Lizzano, R, Bernardini, P, et al. Effect of acute load of grapefruit juice on urinary excretion of citrate and urinary risk factors for renal stone formation. Dig Liver Dis 2002; 34 Suppl 2:S160.
  120. Goldfarb, DS, Asplin, JR. Effect of grapefruit juice on urinary lithogenicity. J Urol 2001; 166:263.
  121. Brinkley, LJ, Gregory, J, Pak, CY. A further study of oxalate bioavailability in foods. J Urol 1990; 144:94.
  122. Hirvonen, T, Pietinen, P, Virtanen, M, et al. Nutrient intake and use of beverages and the risk of kidney stones among male smokers. Am J Epidemiol 1999; 150:187.
  123. Wabner, CL, Pak, CY. Effect of orange juice consumption on urinary stone risk factors. J Urol 1993; 149:1405.
  124. Odvina, CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 2006; 1:1269.
  125. Gettman, MT, Ogan, K, Brinkley, LJ, Adams-Huet, B, et al. Effect of cranberry juice consumption on urinary stone risk factors. J Urol 2005; 174:590.
  126. Kessler, T, Jansen, B, Hesse, A. Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation. Eur J Clin Nutr 2002; 56:1020.
  127. McHarg, T, Rodgers, A, Charlton, K. Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation. BJU Int 2003; 92:765.
  128. Lemann, J Jr. Composition of the diet and calcium kidney stones. N Engl J Med 1993; 328:880.
  129. Jackson, RD, LaCroix, AZ, Gass, M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006; 354:669.
  130. Pak, CY, Odvina, CV, Pearle, MS, et al. Effect of dietary modification on urinary stone risk factors. Kidney Int 2005; 68:2264.
  131. Siener, R, Honow, R, Voss, S, et al. Oxalate content of cereals and cereal products. J Agric Food Chem 2006; 54:3008.
  132. Siener, R, Ebert, D, Nicolay, C, Hesse, A. Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. Kidney Int 2003; 63:1037.
  133. Hess, B, Jost, C, Zipperle, L, et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998; 13:2241.
  134. Liebman, M, Costa, G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 2000; 163:1565.
  135. Lemann, J Jr, Pleuss, JA, Gray, RW, Hoffmann, RG. Potassium administration reduces and potassium deprivation increases urinary calcium excretion in healthy adults [corrected]. Kidney Int 1991; 39:973.
  136. Friedman, PA, Gesek, FA. Calcium transport in renal epithelial cells. Am J Physiol 1993; 264:F181.
  137. Muldowney, FP, Freaney, R, Moloney, MF. Importance of dietary sodium in the hypercalciuria syndrome. Kidney Int 1982; 22:292.
  138. Sakhaee, K, Harvey, JA, Padalino, PK, et al. The potential role of sodium abuse on the risk for kidney stone formation. J Urol 1993; 150:310.
  139. Kok, DJ, Iestra, JA, Doorenbos, CJ, Papapoulos, SE. The effects of dietary excesses in animal protein and in sodium on the composition and crystallization kinetics of calcium oxalate monohydrate in urines of healthy men. J Clin Endocrinol Metab 1990; 71:861.
  140. Breslau, NA, Brinkley, L, Hill, KD, Pak, CYC. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988; 66:140.
  141. Amanzadeh, J, Gitomer, WL, Zerwekh, JE, Preisig, PA. Effect of high protein diet on stone-forming propensity and bone loss in rats. Kidney Int 2003; 64:2142.
  142. Hamm, LL. Renal handling of citrate. Kidney Int 1990; 38:728.
  143. Melnick, JZ, Srere, PA, Eishourbagy, NA, et al. Adenosine triphosphate citrate lyase mediates hypocitraturia in rats. J Clin Invest 1996; 98:2381.
  144. Hess, BH, Ackermann, D, Essig, M, et al. Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: Role of protein intake. J Clin Endocrinol Metab 1995; 80:1916.
  145. Holmes, RP, Goodman, HO, Hart, LJ, Assimos, DG. Relationship of protein intake to urinary oxalate and glycolate excretion. Kidney Int 1993; 44:366.
  146. Lemann, J Jr, Piering, WF, Lennon, EJ. Possible role of carbohydrate-induced calciuria in calcium oxalate kidney-stone formation. N Engl J Med 1969; 280:232.
  147. Abate, N, Chandalia, M, Cabo-Chan, AV Jr, et al. The metabolic syndrome and uric acid nephrolithiasis: Novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65:386.
  148. Levy, FL, Adams-Huet, B, Pak, CY. Ambulatory evaluation of nephrolithiasis: An update of a 1980 protocol. Am J Med 1995; 98:50.
  149. Curhan, GC, Willett, WC, Speizer, FE, et al. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001; 59:2290.
white circle LOG IN
white circle DEMO